Trial Profile
A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms coBRIM
- Sponsors Genentech; Roche
- 30 Oct 2022 Results of pooled analysis form NCT03178851, NCT01689519, NCT02322814, and NCT02788279 of safety analysis, published in the Drug Safety
- 23 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.